Amgen Inc. (NASDAQ:AMGN) Shares Acquired by MRA Advisory Group

MRA Advisory Group grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,033 shares of the medical research company’s stock after purchasing an additional 111 shares during the period. MRA Advisory Group’s holdings in Amgen were worth $269,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $29,000. Hershey Financial Advisers LLC acquired a new position in Amgen in the 2nd quarter worth approximately $30,000. Matrix Trust Co purchased a new position in Amgen during the 3rd quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in shares of Amgen in the third quarter valued at $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $270.19 on Tuesday. The company has a market capitalization of $145.24 billion, a PE ratio of 34.60, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company’s fifty day moving average price is $278.16 and its 200 day moving average price is $308.35.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company posted $4.96 earnings per share. As a group, analysts expect that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 121.90%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AMGN. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Bank of America reissued an “underperform” rating and issued a $256.00 price target on shares of Amgen in a research report on Tuesday, December 10th. Wells Fargo & Company lowered their price objective on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Wolfe Research began coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.